Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) EV-to-Revenue : 2.05 (As of May. 11, 2024)

Tetraphase Pharmaceuticals EV-to-Revenue Chart

Tetraphase Pharmaceuticals Annual Data
	Trend	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19
EV-to-Revenue		Get a 7-Day Free Trial					13.78	1.32	19.43	-1.00	-0.88

Tetraphase Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
EV-to-Revenue	Get a 7-Day Free Trial															1.04	-1.34	-0.47	-0.88	-1.48

Competitive Comparison of Tetraphase Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Tetraphase Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tetraphase Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tetraphase Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tetraphase Pharmaceuticals's EV-to-Revenue falls into.

Tetraphase Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Tetraphase Pharmaceuticals's EV-to-Revenue for today is calculated as:

Tetraphase Pharmaceuticals's current Enterprise Value is $16.07 Mil.
Tetraphase Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tetraphase Pharmaceuticals  (NAS:TTPH) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Tetraphase Pharmaceuticals's PS Ratiofor today is calculated as:

Tetraphase Pharmaceuticals's share price for today is $2.20.
Tetraphase Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.22.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tetraphase Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tetraphase Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Business Description